Smith Chas P & Associates PA Cpas Buys 148,565 Shares of Novo Nordisk A/S $NVO

Key Points

• Smith Chas P & Associates increased its Novo Nordisk stake by 18.5%, buying 148,565 shares to hold 950,151 shares valued at approximately $45.55 million. Other institutional investors have also recently added to or initiated positions.
• Analyst sentiment remains mixed: four analysts rate the stock Buy, 14 rate it Hold and one rates it Sell. Novo Nordisk has an overall Hold rating and an average price target of $64.94.
• NVO recently traded near $43, well below its 52-week high of $64.16. While Wegovy’s China approvals could support future growth, concerns about competition and the semaglutide patent cliff continue to weigh on investor sentiment.

Smith Chas P & Associates PA Cpas grew its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 18.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 950,151 shares of the company's stock after acquiring an additional 148,565 shares during the period. Novo Nordisk A/S comprises approximately 2.2% of Smith Chas P & Associates PA Cpas' investment portfolio, making the stock its 18th biggest holding. Smith Chas P & Associates PA Cpas' holdings in Novo Nordisk A/S were worth $45,550,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of NVO. Godfrey Financial Associates Inc. purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $25,000. Scarborough Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $26,000. Transamerica Financial Advisors LLC boosted its stake in Novo Nordisk A/S by 201.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company's stock worth $31,000 after purchasing an additional 403 shares in the last quarter. Johnson Financial Group Inc. boosted its stake in Novo Nordisk A/S by 128.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 684 shares of the company's stock worth $38,000 after purchasing an additional 384 shares in the last quarter. Finally, Continuum Advisory LLC purchased a new stake in Novo Nordisk A/S during the 2nd quarter worth approximately $38,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. Citigroup reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Zacks Research raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Weiss Ratings raised Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. Finally, Nordea Equity Research upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Friday, June 19th. Four investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and an average price target of $64.94.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy received approval in China for MASH, making it the first GLP-1 receptor agonist in the country approved for the liver disease. The decision expands semaglutide’s potential beyond obesity and diabetes, although Novo has not provided a launch schedule or revenue outlook. Reuters article
• Positive Sentiment: China’s acceptance of Novo’s oral Wegovy application creates a potential avenue into the country’s growing GLP-1 weight-management market. Investors see the opportunity as a possible long-term growth driver, though regulatory approval, launch timing and competitive dynamics remain uncertain. Oral Wegovy China article
• Neutral Sentiment: HSBC raised its price target to 320 Danish kroner but kept a Hold rating, reflecting improved valuation expectations without a strong near-term conviction. HSBC price target article
• Positive Sentiment: Some analysts continue to view Novo’s valuation, strong margins, free cash flow and GLP-1 leadership as providing a margin of safety, suggesting the recent weakness may already reflect substantial execution and competitive risks. Novo Nordisk valuation analysis
• Negative Sentiment: The Morgan Stanley downgrade is the dominant near-term catalyst. Investors are questioning whether oral Wegovy, China expansion and other pipeline opportunities can replace revenue exposed to the semaglutide patent cliff, contributing to NVO’s decline and keeping sentiment weak. Morgan Stanley downgrade article

Novo Nordisk A/S Stock Performance

NVO traded down $0.98 during trading on Friday, reaching $43.03. 11,004,048 shares of the company's stock were exchanged, compared to its average volume of 17,175,861. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The stock has a market capitalization of $192.15 billion, a P/E ratio of 10.52, a price-to-earnings-growth ratio of 1.50 and a beta of 0.74. The company's fifty day simple moving average is $47.63 and its 200-day simple moving average is $43.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. As a group, research analysts predict that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were issued a dividend of $0.5786 per share. This represents a yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S's dividend payout ratio (DPR) is 20.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.